A bone marrow transplant in multiple myeloma is almost always an autologous stem cell transplant: your own blood stem cells are collected, you receive a high dose of chemotherapy to destroy myeloma cells, and then the stored cells are returned to rebuild your blood and immune system. It is a standard part of treatment for fit patients, usually after initial drug therapy, and it aims for a deep, long-lasting remission. For most people it controls myeloma for years rather than curing it.
As a hematologist, I have walked many patients through this process. This guide explains what myeloma is, who is eligible for transplant, each stage of the journey, the side effects to expect, and how life looks afterward.
Multiple Myeloma in Brief
Multiple myeloma is a hematological cancer of plasma cells, the white blood cells that normally make antibodies. Abnormal plasma cells multiply in the bone marrow, crowd out normal blood production, and produce a single abnormal antibody called a paraprotein or M-protein.
Myeloma is usually preceded by a symptomless condition called monoclonal gammopathy of undetermined significance (MGUS). Risk rises with age, and myeloma is more common in men and in people of African descent. The classic features are summed up by the acronym CRAB:
| Feature | What it means | Typical threshold |
|---|---|---|
| C: Calcium | High blood calcium from bone breakdown | Above 11 mg/dL (2.75 mmol/L) |
| R: Renal | Kidney damage from light chains and calcium | Creatinine above 2 mg/dL (177 µmol/L) |
| A: Anemia | Low hemoglobin from marrow crowding | Hemoglobin below 10 g/dL |
| B: Bone | Lytic lesions, pain, fractures | One or more lesions on imaging |
Diagnosis combines blood and urine tests for the paraprotein and free light chains, a bone marrow biopsy showing excess clonal plasma cells, and imaging such as low-dose whole-body CT, MRI, or PET-CT. Chromosome testing on the marrow identifies high-risk features that influence the transplant plan.
Why Transplant Is Used in Myeloma
Melphalan, the chemotherapy used before transplant, kills myeloma cells more effectively at high doses. The problem is that such doses also wipe out the normal bone marrow. Returning your own previously collected stem cells rescues the marrow, making the high dose survivable.
The terms “bone marrow transplant” and “stem cell transplant” are used loosely. Today the stem cells are almost always collected from the bloodstream rather than the marrow itself; our article on bone marrow transplant versus stem cell transplant explains the differences in detail.
| Type | Source of cells | Role in myeloma |
|---|---|---|
| Autologous | Your own stem cells | Standard of care for eligible patients |
| Tandem autologous | Your own cells, two transplants a few months apart | Sometimes used for high-risk disease |
| Allogeneic | A matched donor | Rarely used; mainly in clinical trials or selected young high-risk patients |
Who Is Eligible?
Eligibility depends on overall fitness rather than a strict age cut-off. Transplant is commonly offered to people up to around their early seventies, and sometimes older if they are very fit. The team assesses:
- Heart, lung, liver, and kidney function
- Performance status, meaning how well you manage daily activities
- Response to initial treatment
- Other illnesses and personal preferences
Kidney impairment does not automatically rule out transplant, although the melphalan dose may be reduced. People who are not eligible still have effective drug-based options.
The Transplant Journey Step by Step
- Induction therapy: several months of combination treatment, typically including a proteasome inhibitor such as bortezomib, an immunomodulatory drug such as lenalidomide, and dexamethasone, often with an anti-CD38 antibody like daratumumab. The goal is to shrink the myeloma before transplant.
- Stem cell mobilization and collection: daily injections of a growth factor (G-CSF), sometimes with plerixafor, push stem cells from the marrow into the blood. They are collected through a machine called an apheresis machine, then frozen. Enough cells are often stored for two transplants.
- Conditioning: high-dose melphalan is given, usually as a single intravenous dose.
- Stem cell infusion: a day or two later, the thawed cells are infused through a central line, much like a blood transfusion.
- Engraftment: the new cells travel to the marrow and begin producing blood cells, typically within about two weeks. Until then, you need close monitoring, transfusions if necessary, and protection from infection.
Side Effects and Risks
The toughest period is the first two to three weeks after melphalan, when blood counts are at their lowest. Common effects include:
- Infection risk from very low white cell counts, often treated with antibiotics and preventive medicines
- Mucositis, painful inflammation of the mouth and gut
- Nausea, diarrhea, loss of appetite, and fatigue
- Temporary hair loss
- A need for red cell and platelet transfusions
Because the cells are your own, there is no graft-versus-host disease, which makes autologous transplant far safer than a donor transplant. Serious complications do occur, but treatment-related deaths are uncommon in experienced centers.
Life After Transplant
Most people go home once their counts recover, then continue close follow-up. Energy returns gradually over a few months. Previous childhood and adult vaccinations are repeated because the immune memory is reset.
Maintenance therapy, most often lenalidomide taken daily, is usually started a few months after transplant and continued long term to keep the myeloma in remission. Response is monitored with regular paraprotein and light chain tests, and sometimes with bone marrow testing for minimal residual disease.
If myeloma returns, a second transplant may be an option when the first remission lasted a long time. Newer treatments, including CAR T-cell therapy and bispecific antibodies, have widened the choices for relapsed disease.
Key Takeaways
- Transplant in myeloma is almost always autologous, using your own stem cells.
- It follows induction therapy and uses high-dose melphalan to deepen remission.
- Eligibility is based on fitness, not age alone.
- Maintenance therapy after transplant helps prolong remission.
- It is a powerful treatment, but for most people myeloma remains a chronic condition to be managed.
For more on how marrow works and the conditions that affect it, see our bone marrow guide.
Frequently Asked Questions
Does a stem cell transplant cure multiple myeloma?
For most people it does not cure myeloma, but it can produce a deep remission that lasts for years. Combined with maintenance therapy and newer drugs, it has markedly improved long-term outlook.
How long will I be in hospital?
Many patients stay around two to three weeks, until blood counts recover. Some centers deliver parts of the process as an outpatient, with daily visits and a nearby place to stay.
Do I need a donor?
Usually not. Autologous transplant uses your own cells, so no donor match is needed. Donor transplants are reserved for rare, selected situations.
Can I delay transplant?
Some people collect and store stem cells early, then keep transplant in reserve for first relapse. This is a reasonable option to discuss with your hematologist, weighing your disease risk and preferences.
